Breaking News Instant updates and real-time market news.

AMGN

Amgen

$196.17

-4.26 (-2.13%)

, ARNA

Arena Pharmaceuticals

$37.67

1.29 (3.55%)

04:55
08/09/18
08/09
04:55
08/09/18
04:55

Leerink to hold a tour

West Coast Biotech Bus Tour travels throughout San Francisco and Los Angeles on August 7-9.

AMGN

Amgen

$196.17

-4.26 (-2.13%)

ARNA

Arena Pharmaceuticals

$37.67

1.29 (3.55%)

BMRN

BioMarin

$103.33

-2.51 (-2.37%)

BOLD

Audentes Therapeutics

$36.35

2.15 (6.29%)

CALA

Calithera Biosciences

$5.08

0.575 (12.78%)

CBAY

CymaBay

$11.67

0.28 (2.46%)

DERM

Dermira

$9.92

-0.07 (-0.70%)

IMDZ

Immune Design

$3.45

0.1 (2.99%)

JAZZ

Jazz Pharmaceuticals

$175.61

-4.39 (-2.44%)

KURA

Kura Oncology

$19.05

0.5 (2.70%)

RCUS

Arcus Biosciences

$11.52

0.24 (2.13%)

XNCR

Xencor

$41.73

1.17 (2.88%)

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 14

    Aug

  • 14

    Aug

  • 25

    Aug

  • 30

    Aug

  • 31

    Aug

  • 12

    Sep

  • 27

    Oct

  • 09

    Nov

  • 20

    Dec

AMGN Amgen
$196.17

-4.26 (-2.13%)

07/30/18
PIPR
07/30/18
NO CHANGE
PIPR
Arrowhead pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he would remain a buyer of Arrowhead Pharmaceuticals shares ahead of a "busy" second half of the year. The company could have five RNAi candidates in the clinic this year, and partner Amgen (AMGN) nominated AMG-890 as a clinical candidate that could begin clinical trials this year. Tenthoff reiterated an Overweight rating and $17 price target on Arrowhead shares.
08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
07/27/18
JEFF
07/27/18
NO CHANGE
Target $220
JEFF
Buy
Amgen price target raised to $220 from $200 at Jefferies
Jefferies analyst Michael Yee raised his price target for Amgen to $220 saying the company last night reported "another strong quarter." He thinks Amgen shares "will go well north" of $200-$220 if the company can manage Neulasta biosimilar risk and "take the fears off the table." Yee keeps a Buy rating on the stock.
08/08/18
LEER
08/08/18
NO CHANGE
LEER
Regeneron, Amgen most exposed to Medicare Part B changes, says Leerink
After the Centers for Medicare and Medicaid Services announced that Medicare Advantage plans will have the option in 2019 of applying step therapy for physician-administered and other Part B drugs for new patients, Leerink analyst Geoffrey Porges said the end goal is to create MA plan formularies that can be used as a tool to negotiate with pharmaceutical makers for lower drug prices. Among the stocks he covers, Porges identifies Regeneron (REGN) and Amgen (AMGN) as among those with the most exposure to increased competitive intensity in Part B. For Regeneron, he sees the news re-igniting speculation about the threat of biosimilars and substitution with compounded Avastin, while for Amgen the change means that preference for its growth factor products facing biosimilar competition is likely to be challenged, the analyst said. Regeneron shares are down 4.6% to $373.34 in morning trading, while Amgen is down 2.2% to $195.89.
ARNA Arena Pharmaceuticals
$37.67

1.29 (3.55%)

03/20/18
03/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/18
JMPS
03/20/18
NO CHANGE
Target $79
JMPS
Outperform
Arena Pharmaceuticals price target raised to $79 from $63 at JMP Securities
JMP Securities analyst Jason Butler said Arena Pharmaceuticals' top-line results for etrasimod in ulcerative colitis meet or beat his best-case expectations and he has increased his view of the probability of success for etrasimod in UC to 75% from 50% following the report of the data. Given the higher odds he places on the success of the drug in that indication, Butler raised his price target on Arena shares to $79 from $63 and keeps an Outperform rating on the stock.
03/21/18
SBSH
03/21/18
NO CHANGE
Target $62
SBSH
Buy
Arena Pharmaceuticals price target raised to $62 from $55 at Citi
Citi analyst Joel Beatty raised his price target for Arena Pharmaceuticals to $62 after the company announced positive Phase 2 topline results for etrasimod in ulcerative colitis. The analyst increased his market penetration projections for etrasimod and maintained a 60% probability of success for the drug. He keeps a Buy rating on Arena Pharmaceuticals.
04/19/18
CANT
04/19/18
NO CHANGE
Target $65
CANT
Overweight
Arena's APD371 'another underappreciated asset,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views Arena Pharmaceuticals' APD371 in Crohn's abdominal pain as "another underappreciated asset." Release of data from clinical testing is expected in Q2, but is unlikely to have a significant impact on the stock given its early nature, Tanner tells investors in a research note. He believes, however, that APD371's underlying pharmacology could positively position the drug candidate favorably versus other cannabinoid receptor modulators. The analyst raised his price target for the shares to $65 from $64 and keeps an Overweight rating on Arena Pharmaceuticals.
BMRN BioMarin
$103.33

-2.51 (-2.37%)

08/07/18
PIPR
08/07/18
NO CHANGE
Target $120
PIPR
Overweight
BioMarin competitive positioning 'improved measurably,' says Piper Jaffray
Spark Therapeutics' (ONCE) update this morning for hemophilia A candidate SPK-8011 was disappointing both efficacy- and safety-wise, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Spark Fails to Ignite; Valrox Competitive Positioning Just Improved Measurably." He believes the news "goes a long way" to putting this potential threat to BioMarin (BMRN) "to bed." The analyst is incrementally positive on BioMarin's competitive positioning in hemophilia A and keeps an Overweight rating on the shares with a $120 price target. The Spark data compares unfavorably to BioMarin's valrox, Raymond writes. He remains a buyer of BioMarin with an Overweight rating and $120 price target. The stock in premarket trading is up $5.55 to $103.50.
08/08/18
RHCO
08/08/18
NO CHANGE
Target $61
RHCO
Buy
Spark Therapeutics price target lowered to $61 from $102 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Spark Therapeutics (ONCE) to $61, saying the company's SPK-8011 update has dimmed the outlook for its hemA program. Nash notes that while the FVIII activity reached the 30% threshold set by his physician consultants, it is below that of BioMarin (BMRN) BMN-270, adding the immune risk cannot be eliminated from the treatment. The analyst keeps his Buy rating on Spark Therapeutics, citing expectations of a gradual uptake of its Luxturna in 2018 with modeled commercial opportunity of $322M. Nash adds that Luxturna's commercial success should deepen the company's understanding of hemophilia and help differentiate its products from competitors.
08/07/18
STFL
08/07/18
INITIATION
Target $114
STFL
Buy
BioMarin transferred with a Buy at Stifel
Stifel transferred coverage of BioMarin to analyst Paul Matteis, who set a Buy rating and $114 price target on the shares. He sees the approved product base having a path to about $2B in 2019 revenue, which provides a share floor of about $80 ahead of a handful of clinical catalysts during the next 12-18 months, Matteis tells investors. BioMarin is better positioned than most mature biotechs in terms of drug pricing pressure and competition risk, added the analyst.
08/08/18
MZHO
08/08/18
NO CHANGE
Target $77
MZHO
Buy
Spark Therapeutics price target lowered to $77 from $91 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Spark Therapeutics (ONCE) to $77 after the company provided an update on the SPK-8011 program for hemophilia A. While the latest data appears "somewhat mixed" with two out of the seven patients not maintaining Factor VIII level of at least 12%, Spark offered a reasonable explanation and proposal to address the issue in the upcoming Phase III trial that is scheduled to begin in Q4, Yang tells investors in a research note. The analyst finds it premature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN). Yang removed a takeover premium for Spark in her new price target but keeps a Buy rating on the shares.
BOLD Audentes Therapeutics
$36.35

2.15 (6.29%)

08/08/18
MZHO
08/08/18
UPGRADE
Target $45
MZHO
Buy
Audentes Therapeutics upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded Audentes Therapeutics to Buy and raised her price target for the shares to $45 from $38. The analyst is "increasingly positive" on the company's AT-132 program. X-Linked myotubular myopathy patients treated so far with AT-132 continue to show significant improvements in neuromuscular and respiratory function, Yang tells investors in a research note.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $45
PIPR
Overweight
Audentes update on AT132 should put concerns to rest, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says Audentes Therapeutics provided an "incrementally positive" clinical update for lead asset AT132 when reporting Q2 results this morning. With all patients now experiencing "meaningful" reductions of ventilator time and "now impressive" muscle biopsy data, questions around this drug's clinical activity and therapeutic window "should be put to rest," Raymond tells investors in a research note. The analyst believes the only question that remains is around optimal dose. He continues to recommend purchase of Audentes Therapeutics with an Overweight rating adn $45 price target.
06/25/18
CHDN
06/25/18
INITIATION
Target $36
CHDN
Neutral
Audentes Therapeutics initiated with a Neutral at Chardan
Chardan analyst Gbola Amusa initiated Audentes Therapeutics with a Neutral and $35 price target.
05/21/18
MZHO
05/21/18
NO CHANGE
Target $38
MZHO
Neutral
Audentes Therapeutics price target raised to $38 from $26 at Mizuho
Mizuho analyst Difei Yang raised his price target for Audentes Therapeutics to $38 saying she's "very encouraged" by the updated data from AT-132, which showed continued improvements in the first cohort of patients, as well as early positive data in the expansion cohort. The analyst now sees a "stronger probability of success" for the AT-132 program. She keeps a Neutral rating on Audentes Therapeutics shares due to valuation.
CALA Calithera Biosciences
$5.08

0.575 (12.78%)

02/16/18
SBSH
02/16/18
UPGRADE
Target $14
SBSH
Buy
Calithera Biosciences upgraded to Buy from Neutral at Citi
Citi analyst Robyn Karnauskas upgraded Calithera Biosciences (CALA) to Buy with an unchanged price target of $14. The stock has been under pressure after Phase 1 data from the CB-839/PD-1 combo, presumably due to comparison to Nektar Therapeutics' (NKTR) combo data, Karnauskas tells investors in a research note. She believes this is an unfair comparison, as Calithera and Nektar are targeting different patient populations, and the drugs have different mechanisms. The analyst views Calithera as underappreciated with the stock trading above cash with only $2 per share for the pipeline.
10/05/17
WBLR
10/05/17
INITIATION
WBLR
Outperform
Calithera Biosciences initiated with an Outperform at William Blair
William Blair analyst Matthew Phipps started Calithera Biosciences with an Outperform rating. The analyst sees clinical catalysts and a "clear development path" with the company's wholly owned glutaminase inhibitor, CB-839, driving share outperformance in the coming months.
CBAY CymaBay
$11.67

0.28 (2.46%)

06/28/18
RAJA
06/28/18
INITIATION
Target $20
RAJA
Outperform
CymaBay initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated CymaBay with an Outperform and $20 price target.
04/16/18
ROTH
04/16/18
NO CHANGE
Target $27
ROTH
Buy
CymaBay seladelpar a 'clear winner' from EASL, says Roth Capital
Roth Capital analyst Yasmeen Rahimi notes that Novartis (NVS) reported disappointing 28-day interim results from its FXR agonist in 49 PBC patients at EASL. Tropifexor had AP level drops far below CymaBay's (CBAY) seldelpar at 4 weeks, she points out, adding that she believes seladelpar is a "clear winner" from Paris. Rahimi reiterates a Buy rating and $27 price target on CymaBay's shares.
06/06/18
HCWC
06/06/18
NO CHANGE
Target $23
HCWC
Buy
CymaBay price target raised to $23 from $21 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay Therapeutics to $23 saying the company is well positioned to successfully execute its strategy with seladelpar. The analyst reiterates a Buy rating on the shares.
04/13/18
HCWC
04/13/18
NO CHANGE
Target $21
HCWC
Buy
CymaBay price target raised to $21 from $18 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay Therapeutics to $21 saying results from a second interim analysis of the ongoing one-year open-label Phase 2 study of seladelpar in primary biliary cholangitis patients are "strongly positive" and better than expected. The data show "robust and sustained" efficacy at 26 weeks, a clear dose response and reductions in pruritus, Arce tells investors in a research note. He believes seladelpar possesses the leading clinical profile to support second-line treatment. The analyst affirms a Buy rating on CymaBay.
DERM Dermira
$9.92

-0.07 (-0.70%)

05/25/18
NEED
05/25/18
NO CHANGE
Target $16
NEED
Buy
Dermira price target lowered to $16 from $19 at Needham
Needham analyst Serge Belanger lowered his price target on Dermira to $16 after the company's inaugural analyst day which focused on the commercial launch strategy for DRM04 to reflect the higher than anticipated launch costs for the program. The analyst keeps his Buy rating however, saying his expectations for FDA approval of DRM04 are high given the "solid" phase 3 data, forecasting the treatment to have a significant role in the hyperhidrosis market which currently has few effective alternatives. Belanger adds that the stock price "undervalues DRM04's potential and largely ignores the lebrikizumab program".
05/25/18
CANT
05/25/18
NO CHANGE
Target $20
CANT
Overweight
Dermira 23% selloff not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says she sees no fundamental reason for the 23% decline yesterday in shares of Dermira. The analyst day underscored the opportunities for glycopyrronium tosylate in excessive sweating and Lebrikizumab in atopic dermatitis, Chen tells investors in a research note. She believes glycopyrronium tosylate approval should drive the stock higher and keeps an Overweight rating on the name with a $20 price target. Chen notes that investors she spoke with were concerned that consensus numbers need to come down.
03/06/18
NEED
03/06/18
NO CHANGE
Target $19
NEED
Buy
Dermira price target lowered to $19 from $43 at Needham
Needham analyst Serge Belanger lowered his price target on Dermira to $19 from $43 after the company's failed DRM01 acne program due to "surprising and disappointing failures across the phase 3 CLAREOS trials". Belanger states that the focus now shifts to Dermira's other assets such as hyperhidrosis which has a PDUFA at the end of June and lebrikizumab which is currently in a phase 2 study with expected readout in mid-2019. The analyst keeps his Buy rating, noting that the sell-off following the DRM01 announcement does not take into account Dermira's remaining asset values.
03/06/18
GUGG
03/06/18
DOWNGRADE
GUGG
Neutral
Dermira downgraded to Neutral from Buy at Guggenheim
IMDZ Immune Design
$3.45

0.1 (2.99%)

09/14/17
RBCM
09/14/17
INITIATION
Target $20
RBCM
Outperform
Immune Design initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Immune Design with an Outperform rating and $20 price target.
10/17/17
RBCM
10/17/17
NO CHANGE
Target $23
RBCM
Outperform
Immune Design weakness a buying opportunity, says RBC Capital
RBC Capital said Outperform rated Immune Design's positive FDA feedback on Phase III Trial for CMB305 is a de-risking event. The firm's analyst said the timeline could be pushed back slightly, but improves ultimate POS, while maintaining optionality. RBC recommends buying shares on weakness and raised the price target on shares to $23 from $20 .
10/17/17
WELS
10/17/17
DOWNGRADE
WELS
Market Perform
Immune Design downgraded to Market Perform from Outperform at Wells Fargo
JAZZ Jazz Pharmaceuticals
$175.61

-4.39 (-2.44%)

07/13/18
WELS
07/13/18
NO CHANGE
Target $182
WELS
Outperform
Jazz 'confident' in defending Xyrem in District Court, says Wells Fargo
Following news that the U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal Pharmaceuticals (AMRX) that patents owned by Jazz Pharmaceuticals (JAZZ) related to its Xyrem drug are invalid, Wells Fargo analyst David Maris tells investors in a research note that he spoke with Jazz this morning and they said they "feel confident" in defending Xyrem in the District Court should the case go to trial. Additionally, Jazz, which said a trial date has not yet been set, said they have now settled with 8 out of 9 of the District Court challenges. Maris believes the reaction today is "overdone," as Jazz still has a strong portfolio to defend Xyrem and the company has shown a clear willingness to settle.
07/16/18
PIPR
07/16/18
NO CHANGE
Target $211
PIPR
Overweight
Jazz court ruling does not threaten Xyrem durability, says Piper Jaffray
A federal appellate court on Friday affirmed that certain claims surrounding a number of patents covering Jazz Pharmaceuticals' Xyrem REMS program are invalid, Piper Jaffray analyst David Amsellem tells investors in a research note. The analyst would not view the decision as a threat to the durability of Xyrem out to 2023. He continues to believe that Jazz's visibility into earnings growth in the double-digits is high, owing to contribution from newer products. Amsellem believes the company has "significant room for further value creation" and keeps an Overweight rating on Jazz with a $211 price target.
07/16/18
CANT
07/16/18
NO CHANGE
Target $203
CANT
Overweight
Cantor sees 'meaningful upside' in shares of Jazz Pharmaceuticals
Cantor Fitzgerald analyst William Tanner sees "meaningful upside" in shares of Jazz Pharmaceuticals from current levels. The analyst views recent legal developments as positive, "on balance," and thinks any announcement on the business development front "could be a major incremental driver of positive sentiment." He reiterates an Overweight rating on Jazz with a $203 price target.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
KURA Kura Oncology
$19.05

0.5 (2.70%)

02/16/18
SBSH
02/16/18
NO CHANGE
Target $28
SBSH
Buy
Kura Oncology price target raised to $28 from $19 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $28 citing increased confidence that Tipifarnib is a differentiated therapy for the treatment of HRAS mutant head and neck squamous cell cancer. The analyst sees a 55% probability of success. It is more probable than not that the five of eight, or 63% response rate observed thus far in head and neck squamous cell cancer is a "real efficacy signal," and the duration of response in this indication reinforces this view, Beatty tells investors in a research note. The analyst keeps a Buy rating on Kura Oncology.
08/01/18
HCWC
08/01/18
INITIATION
Target $31
HCWC
Buy
Kura Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Kura Oncology with a Buy rating and $31 price target. The shares currently do not reflect the overall opportunity for tipifarnib, which is about to enter a pivotal program in head and neck squamous cell carcinoma patients as well as several other indications, which could lead to a broad label for the drug, Pantginis tells investors in a research note.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $35
OPCO
Outperform
Kura Oncology price target raised to $35 from $27 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $35 from $27, citing an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
02/16/18
OPCO
02/16/18
NO CHANGE
Target $30
OPCO
Outperform
Kura Oncology price target raised to $30 from $17.50 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $30 citing the positive updated preliminary results from the company's Phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma. The analyst increased her estimated revenue in 2020-2022 by 66.7% per year. She keeps an Outperform rating on Kura Oncology.
RCUS Arcus Biosciences
$11.52

0.24 (2.13%)

04/09/18
04/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) initiated with a Neutral at UBS. 2. Northern Oil and Gas (NOG) initiated with a Buy at Stifel. 3. Camtek (CAMT) initiated with an Outperform at Northland. 4. Ares Management (ARES) initiated with a Buy at UBS. 5. Arcus Biosciences (RCUS) initiated with an Outperform at Leerink, a Buy at Citi, and a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
LEER
04/09/18
INITIATION
Target $21
LEER
Outperform
Arcus Biosciences initiated with an Outperform at Leerink
Leerink initiated Arcus Biosciences with an Outperform and $21 price target.
04/09/18
SBSH
04/09/18
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.
04/09/18
GSCO
04/09/18
INITIATION
Target $18
GSCO
Neutral
Arcus Biosciences initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter started Arcus Biosciences with a Neutral rating and $18 price target. The analyst sees a lack of near-term pipeline catalysts for the shares.
XNCR Xencor
$41.73

1.17 (2.88%)

06/07/18
06/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Xencor (XNCR) initiated with a Buy at BTIG. 2. Donnelley Financial Solutions (DFIN) initiated with a Buy at DA Davidson. 3. Axsome Therapeutics (AXSM) initiated with a Buy at H.C. Wainwright. 4. ShotSpotter (SSTI) initiated with an Outperform at JMP Securities. 5. WellCare (WCG) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
ADAM
08/08/18
NO CHANGE
Target $45
ADAM
Buy
Xencor price target raised to $45 from $38 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $45 from $38 noting the clinical data for the company's first bi-specific, XmAb, is on track for 2018. She said there are four other bi-specifics that are complete, giving it a pipeline that is very attractive. Lee reiterated her Buy rating on Xencor shares.
06/06/18
BTIG
06/06/18
INITIATION
Target $56
BTIG
Buy
Xencor initiated with a Buy at BTIG
BTIG analyst Dane Leone started Xencor with a Buy rating and $56 price target. The analyst is optimistic for the use of XmAb5871 in the treatment of systemic lupus erythematosus into the Phase 2 read-out during the second half of 2018. Further, he believes the commercialization of Xencor's partner assets, ALXN1210 and MOR208, should help support its cash flow for the next several years.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $52
PIPR
Overweight
Xencor price target raised to $52 from $46 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Xencor to $52 following the company's Q2 results. The company remains a top pick for its bispecific antibody and cytokine pipeline to treat cancer, Tenthoff tells investors in a research note. He notes Xencor has $555M of cash and reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:10
08/17/18
08/17
17:10
08/17/18
17:10
Hot Stocks
Boeing awarded $152.5M U.S. Navy contract »

Boeing is awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:09
08/17/18
08/17
17:09
08/17/18
17:09
Hot Stocks
Boeing awarded $217M Defense Department contract »

The Boeing Co has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$210.37

0.56 (0.27%)

17:08
08/17/18
08/17
17:08
08/17/18
17:08
Hot Stocks
L3 Technologies awarded $240M Defense Department contract »

L-3 Communications was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSGX

Histogenics

$2.65

-0.05 (-1.85%)

17:06
08/17/18
08/17
17:06
08/17/18
17:06
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$67.45

1.79 (2.73%)

, DCT

DCT Industrial

$68.77

1.805 (2.70%)

16:58
08/17/18
08/17
16:58
08/17/18
16:58
Conference/Events
DCT Industrial to host special shareholder meeting »

Special Shareholder…

PLD

Prologis

$67.45

1.79 (2.73%)

DCT

DCT Industrial

$68.77

1.805 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:56
08/17/18
08/17
16:56
08/17/18
16:56
Hot Stocks
Westlake Chemical expands share repurchase program by $150M »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

SM

SM Energy

$27.38

0.17 (0.62%)

16:55
08/17/18
08/17
16:55
08/17/18
16:55
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

PENN

Penn National

$33.04

0.86 (2.67%)

16:51
08/17/18
08/17
16:51
08/17/18
16:51
Hot Stocks
Penn National CEO acquires 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

16:49
08/17/18
08/17
16:49
08/17/18
16:49
Periodicals
U.S. wants Facebook to help wiretap Messenger for criminal probe, Reuters says »

The U.S. government is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:46
08/17/18
08/17
16:46
08/17/18
16:46
Hot Stocks
Westlake Chemical raises quarterly dividend 19% to 25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

EAST

Eastside Distilling

$7.40

-0.01 (-0.13%)

16:45
08/17/18
08/17
16:45
08/17/18
16:45
Syndicate
Breaking Syndicate news story on Eastside Distilling »

Eastside Distilling files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$12.80

-0.095 (-0.74%)

16:44
08/17/18
08/17
16:44
08/17/18
16:44
Syndicate
Spark Networks files to sell 515,416 ordinary shares for holders »

Including 222 ordinary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHPA

Avista Healthcare Public Acquisition Corp.

$10.12

(0.00%)

16:42
08/17/18
08/17
16:42
08/17/18
16:42
Hot Stocks
Avista Healthcare Public Acquisition Corp., Organogenesis announce combination »

Avista Healthcare Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCF

TCF Financial

$25.84

0.17 (0.66%)

16:41
08/17/18
08/17
16:41
08/17/18
16:41
Hot Stocks
TCF Financial COO sells 77,725 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$22.95

-0.11 (-0.48%)

16:38
08/17/18
08/17
16:38
08/17/18
16:38
Recommendations
Lionsgate analyst commentary at Barrington »

Lionsgate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

16:35
08/17/18
08/17
16:35
08/17/18
16:35
General news
Breaking General news story  »

Moody's cuts Turkey…

MSL

MidSouth Bancorp

$14.90

0.1 (0.68%)

16:32
08/17/18
08/17
16:32
08/17/18
16:32
Hot Stocks
MidSouth Bancorp says 'will carefully review' letter sent by Jacobs Asset Mgt. »

MidSouth Bancorp issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EME

EMCOR

$77.96

1.005 (1.31%)

16:31
08/17/18
08/17
16:31
08/17/18
16:31
Hot Stocks
Emcor CEO sells 23,434 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/17/18
08/17
16:30
08/17/18
16:30
Options
Preliminary option volume of 22.3M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.